Effect of the 5-HT\textsubscript{4} receptor agonist tegaserod on the expression of GRK2 and GRK6 in the rat gastrointestinal tract

Teshome Nedi\textsuperscript{1,2}, Paul J. White\textsuperscript{1}, Ian M. Coupar\textsuperscript{1} and Helen R. Irving\textsuperscript{1,3}\textsuperscript{*}

Abstract

Objective: Tegaserod is a 5-hydroxytryptamine type 4 (5-HT\textsubscript{4}) receptor agonist, formerly used in treating constipation predominant irritable bowel syndrome, which desensitizes 5-HT\textsubscript{4} receptors in rat oesophagus and colon in vitro. Desensitization of 5-HT\textsubscript{4} receptors is regulated by G-protein coupled receptor kinases. This study was designed to assess the effect of 5-HT\textsubscript{4} receptor activation on the expression of GRK2 and GRK6 in the rat oesophagus and distal colon by acute administration of tegaserod.

Results: Rats were treated with a single dose of tegaserod (5 mg/kg) and tissue samples of the oesophagus and distal colon were prepared and level of GRK2 and GRK6 protein expression was determined using western blotting. The immunodensity of GRK2 and GRK6 was normalized against the loading control β-actin and compared with control animals. Acute administration of tegaserod for 1, 2, 3, 4, 6, and 8 h did not change significantly the immunodensity of GRK2 or GRK6 in the oesophagus or GRK2 in the distal colon when compared with control animals. This may indicate that the basal level of GRK2 and GRK6 expression is sufficient to regulate the desensitization of 5-HT\textsubscript{4} receptors in acute drug treatment.

Keywords: Colon, Oesophagus, 5-HT\textsubscript{4} receptors, G protein coupled receptor kinases, Receptor desensitization

Introduction

5-Hydroxytryptamine type 4 (5-HT\textsubscript{4}) receptor agonists have prokinetic effects in the gastrointestinal tract stimulating motility and secretion through enhanced acetylcholine release from excitatory motor neurons and interneurons [1]. Tegaserod is a 5-HT\textsubscript{4} receptor agonist with clinical efficacy in patients with constipation-predominant irritable bowel syndrome and chronic constipation [2]. Tegaserod was used for the treatment of constipation-predominant irritable bowel syndrome in females and chronic constipation for both males and females until withdrawn in 2007 as it was associated with rare adverse cardiovascular effects [2, 3]. Tegaserod increases gastric emptying and accelerates small intestine and colonic transit in healthy human subjects [4] but increases colonic transit without altering gastric emptying in patients with constipation-predominant irritable bowel syndrome [5]. Tegaserod has a low therapeutic gain of 5–12% above placebo and is poorly absorbed with about two-thirds of oral doses being eliminated in the faeces [6]. It facilitates the peristaltic reflex in mouse, rat, guinea-pig and human intestine and also attenuates sensory neurotransmission in human rectum [7–12]. Tegaserod increased the amplitude of evoked excitatory postsynaptic currents in cultured myenteric neurons from mice, which desensitized rapidly, making it difficult to obtain responses to higher concentrations [13]. In addition, tegaserod desensitizes 5-HT\textsubscript{4} receptors in rat oesophagus and colon in vitro [14, 15].

G protein coupled receptor (GPCR) kinase (GRK) regulated homologous desensitization has been reported for 5-HT\textsubscript{4} receptors in mouse colliculus neurons and rat oesophagus and colon [14–17]. Cell culture studies
using co-expression of GRKs with different 5-HT$_4$ receptor splice variants showed the involvement of GRK2 and GRK5 in desensitization [18–20]. In contrast, desensitization of 5-HT$_4$ receptors has been associated with GRK6 in the oesophagus and both GRK2 and GRK6 in the distal colon of the rat [15].

Changes in the level of GRK expression elicited by in vivo stimulation or blockade of GPCRs by agonist and antagonist is complex and not predictable [21, 22]. For example, chronic treatment with desipramine (a noradrenaline reuptake blocker) and acute treatment with fluoxetine (a 5-HT reuptake blocker) did not change significantly the immunodensity of GRK2/3 [23]. While chronic treatment with both opioid agonists and antagonists increases the expression of GRK2 and GRK6 in the brain [24, 25]. The molecular mechanisms associated with the regulation of 5-HT$_4$ receptors in vivo by specific GRKs after treatment with 5-HT$_4$ receptor agonist has not been studied. Therefore, the aim of this study was to assess the effect of 5-HT$_4$ receptor activation on the expression level of GRK2 and GRK6 in the rat oesophagus and distal colon by acute administration of tegaserod.

**Main text**

**Methods**

Adult male Sprague–Dawley rats (Monash Animal Services) weighing 200–280 g were randomly divided into six treatment groups and one control group (n = 6; total number = 42). Rats were housed at the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University’s animal facility in a 12 h light–dark cycle with food and water ad libitum. Rats were treated with a single intraperitoneal injection of tegaserod maleate (Sequoia Research Products Ltd, Berkshire, UK) (5 mg/kg) dissolved in vehicle (10% sulfobutyl ether-beta cyclodextrin) or just vehicle (controls). Rats were killed 1 h after vehicle or 1, 2, 3, 4, 6 and 8 h after drug administration by carbon dioxide asphyxiation. Animals were quickly dissected and the lower third of the oesophagus proximal to the diaphragm, and the distal colon were excised. The outer muscularis externa of the oesophagus was separated from the inner tunica muscularis mucosae. Tissues were washed three times with ice-cold phosphate buffered saline (PBS) and homogenized in 1:10 (w/v) of homogenization buffer [50 mM Tris—HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, complete protease inhibitor cocktail tablet (Roche, Sydney, Australia)] for 1 min before centrifugation at 12,000 × g for 10 min. Supernatant protein concentration was determined by Quant-It protein assay (Invitrogen) and homogenates were stored at −80 °C until used.

Total protein (50 µg) was separated on 12% polyacrylamide gels by SDS-PAGE and transferred to nitrocellulose membranes (Amersham Bioscience). Each gel was run with a sample from control to all test groups. Nonspecific binding to the membrane was blocked with Odyssey blocking buffer (LI-COR Biosciences) for 1 h. Membranes were probed with combination of two primary antibodies: goat anti-β-actin and either mouse anti-GRK2 or rabbit anti-GRK6 (Table 1) overnight at 4 °C and washed four times with PBS and 0.1% Tween 20 PBS (PBST). Membranes were incubated with fluorophore-conjugated secondary antibodies (Table 1) for 1 h at room temperature and washed four times for five min using PBST. An Odyssey Infrared Imaging System (LI-COR Biosciences) was used to examine the immunoblots. The integrated optical density of the immunoreactivity was assessed using the Odyssey Infrared Imaging System software (LI-COR Biosciences). The integral optical density of GRK2 and GRK6 from each lane was normalised against β-actin for that lane and expressed as percentage of control values.

Data for each treatment group was expressed as mean ± standard error of mean (SEM) of GRK2 and GRK6 levels expressed as percentage of control values. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, California USA). Values were compared between the different groups using one-way analysis of variance (ANOVA) followed with Dunnett’s multiple comparison post hoc test. A P value < 0.05 was considered to be statistically significant.

| Table 1 Details of primary and secondary antibodies |
|-----------------------------------------|----------------|----------------|----------------------------------|----------------|
| **Antigen** | **Host species** | **Dilution** | **Sources** | **References** |
| β-Actin | Goat | 1:500 | Abcam | |
| GRK2 | Mouse | 1:500 | Santa Cruz; sc-13143 | [15, 36–38] |
| GRK6 | Rabbit | 1:300 | Santa Cruz; sc-566 | [15, 21, 39, 40] |
| Anti-mouse IRDye 800CW | Donkey | 1:10,000 | LI-COR Biosciences; 925-32212 | |
| Anti-goat IRDye 680RD | Donkey | 1:10,000 | LI-COR Biosciences; 925-68074 | |
| Anti-rabbit IRDye 800CW | Donkey | 1:10,000 | LI-COR Biosciences; 925-32213 | |
Results
Immunoblot analysis of the tissue homogenate of the oesophagus and distal colon revealed immunoreactive protein of around 80 kDa for GRK2 or alternatively 66 kDa for GRK6 under the 800 nm excitation wavelength channel and around 42 kDa for β-actin under the 700 nm excitation wavelength channel on the same membrane (Fig. 1). This allowed the analysis of the immunodensity of GRK2 and β-actin or GRK6 and β-actin on the same membrane. The immunodensity of GRK2 relative to β-actin did not change significantly in either the oesophagus (P = 0.52, one-way ANOVA) or distal colon (P = 0.66, one-way ANOVA) following acute treatment with tegaserod (Fig. 1a, b). Similarly, the immunodensity of GRK6 relative to β-actin in the oesophagus (Fig. 1c) not change significantly (P = 0.92, one-way ANOVA) following acute treatment with tegaserod.

Discussion
This study was designed to investigate the effect of acute activation of 5-HT4 receptors using the 5-HT4 receptor agonist tegaserod on the expression level of GRK2 and GRK6 in rat oesophagus and distal colon. Prior studies indicate that in the oesophagus GRK6 is associated with the desensitization of 5-HT4 receptors whilst GRK2 and GRK6 are associated with desensitization of 5-HT4 receptors in the distal colon of the rat [15]. GRK-mediated GPCR desensitization has a physiological significance to protect cells from over-stimulation in the persistent presence of agonists and to keep the signals under regulation. Up-regulation of GRKs facilitates GPCR desensitization whilst down-regulation of GRKs impedes GPCR desensitization in vitro and in vivo [26].

Intravenous administration of tegaserod (0.001–1 mg/kg) has been reported to evoke a dose-dependent increase in relaxation of the longitudinal muscle of the rat oesophagus. The response had a rapid onset (commencing less than 1 min after dosing) and reached a maximum typically within 2 min [27–29]. In addition, subcutaneous administration of tegaserod (0.03, 0.3 and 3 mg/kg) has been reported to produce a dose-dependent colonic prokinetic effect in guinea-pigs [30]. Moreover, intraperitoneal administration of tegaserod (0.1, 1, 10 mg/kg) has been reported to produce a dose-dependent reduction in the number of abdominal contractions induced by colonic distensions in rats [8]. Based on the above studies a single dose of tegaserod (5 mg/kg i.p.) was used for time course study of the effect of 5-HT4 receptor activation on the level of expression of GRK2 and GRK6 in the rat oesophagus and distal colon.

Similar to the finding of the present in vivo study, acute treatment with the 5-HT reuptake blocker fluoxetine that increases the synaptic concentration of 5-HT, was not associated with changes in the immunodensity of GRK2/3 in rat frontal cortex membrane and cytosolic fractions [23]. In contrast, acute treatment with tricyclic antidepressant desipramine increased in a dose and time-dependent manner the content of GRK2/3 in the membrane whilst chronic treatment did not alter the immunodensity of GRK2/3 [23].

Tegaserod activates 5-HT4 receptors on intrinsic primary afferent neurons and mimics the action of endogenous serotonin released from enterochromaffin cells. It stimulates the intrinsic primary afferent neurones that release transmitters such as calcitonin gene-related peptide, which activate cholinergic interneurons. The
cholinergic interneurons activate the peristaltic reflex [9]. Tegaserod has been shown to desensitize the peristaltic reflex induced by mucosal stimulation in a time and concentration dependent manner in rat colon [14]. In addition, in rat oesophagus, tegaserod desensitized 5-HT induced-relaxation of the tunica muscularis mucosae in a time-dependent manner [15]. The lack of change in the expression level of GRK2 in the oesophagus (Fig. 1a) is in line with the immunohistochemistry study showing that there was no expression of GRK2 on the smooth muscle of the muscularis mucosae where the 5-HT4 receptors are concentrated in the oesophagus [15, 31, 32]. The interesting finding is the lack of change in the expression level of GRK6 in the oesophagus and GRK2 in distal colon tissues (Fig. 1b, c) where they were found to be co-expressed and co-immunoprecipitated with 5-HT4 receptors [15]. This may be due to the expression of sufficient levels of GRK2 and GRK6 at the basal level to regulate the desensitization of 5-HT4 receptor. Alternatively, it may require chronic administration of tegaserod to obtain changes in the expression level of GRK2 and GRK6. The desensitization of GPCRs requires translocation of GRK2 from cytosol to membrane upon activation by agonist [33]. Analysis of change in the immunoreactivity of GRK2 in the membrane fraction warrant further investigation.

In the distal colon, 5-HT4 receptor immunoreactive cells were found in longitudinal muscle, myenteric plexuses, circular muscle, submucosal plexuses and muscularis mucosae. GRK6 was expressed in the longitudinal muscle, circular muscle, and muscularis mucosae and co-immunoprecipitated with 5-HT4 receptors [15]. Due to the interference of the background it was not possible to quantify the immunodensity of GRK6. In addition, the 5-HT4 receptors are located presynaptically at neuronal synapses within the myenteric plexus [1] and GRK5 is exclusively localised on the nerve endings of both myenteric and submucosal plexuses [15]. It is therefore worthwhile to investigate the effect of tegaserod on the expression of GRK5 and GRK6 at mRNA level in the distal colon.

Based on desensitization studies of β2-adrenoceptors and M3 muscarinic receptors, it is often generalized that partial agonists induce less desensitization of GPCRs than full agonists. They could stabilize receptor conformations that differ in their capacity to interact or serve as substrates for GRKs and arrestins to generate downstream recognition barcodes [34, 35]. Partial agonists augment submaximal endogenous stimulation and prevent an exaggerated response to an endogenous agonist. As a result partial agonists have a lower tendency to induce receptor desensitization and/or receptor down-regulation [34, 35]. However, the capacity of agonists to induce desensitization of 5-HT4 receptors depends more on the activation potency of the drug than its efficacy [16]. The lower potency of tegaserod may contribute to the lack of its effect on the expression level of GRKs in rat oesophagus and distal colon. Alternatively, tegaserod has similar binding affinities to both 5-HT4 and 5-HT2B receptors [30] and acts as an antagonist at the 5-HT2B receptor [29, 30]. Thus, the 5-HT2B receptor antagonist effect of tegaserod may counteract its effect on the expression level of GRKs.

Limitations

Limitations of this study include the use of only one concentration of tegaserod. However, the concentration used reduces the number of abdominal contractions induced by colonic distensions in rats measured over 90 min [8]. Taken together with prior observations that desensitization is only detectable after 20 min in rat oesophagus [15], our sampling times of 1–8 h should detect changes in GRK expression. Another limitation is the use of a control at only a single time point, which occurred in part to restrict animal usage. A further limitation is the lack of positive control for changes in GRK2 and 6 expression although prior study [15] indicated that the antisera used detected changes in the expression level of these proteins. So far, no studies have investigated the effect of 5-HT4 receptor activation on the expression level of GRKs using agonists with different potency, selectivity and efficacy. Such studies will help understand whether the expression of GRKs is altered based on agonist potency, selectivity or efficacy in physiological systems.

Abbreviations

5-HT4: 5-hydroxytryptamine type 4; ANOVA: one-way analysis of variance; GPCR: G-protein coupled receptor; GRK: GPCR kinase; PBS: phosphate buffered saline; PBST: phosphate buffered saline Tween; SEM: standard error of mean.

Authors’ contributions

TN designed and undertook the experiments. TN, IC, PW and HI were involved in data analyses and interpretation. TN and HI drafted the manuscript. All authors read and approved the final manuscript.

Author details

1 Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, VIC 3052, Australia. 2 School of Pharmacy, College of Health Sciences, Addis Ababa University, PO Box 1176, Addis Ababa, Ethiopia. 3 La Trobe Institute for Molecular Science, La Trobe University, PO Box 199, Bendigo, VIC 3552, Australia.

Acknowledgements

The authors are grateful to Dr. RJ Prankerd (Monash University) for providing the SBE/CD.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed in this study are included in the published article.
Consent for publication
Not applicable.

Ethics approval and consent to participate
All procedures conformed to Australian National Health and Medical Research Council’s guidelines and were approved by the Victorian College of Pharmacy Animal Ethics Committee of Monash University. Rats were housed at the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University’s animal facility in a 12 h light–dark cycle with food and water ad libitum.

Funding
The Faculty of Pharmacy and Pharmaceutical Sciences, Monash University supported the experimental work and provided a PhD stipend to TN.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 21 April 2018 Accepted: 6 June 2018
Published online: 08 June 2018

References
1. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397–414.
2. Beattie DT, Smith IAM. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn-Schmiedeberg’s Arch Pharmacol. 2008;377:181–203.
3. McLean PG, Borman RA, Lee K. S-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci. 2007;30:9–13.
4. Degen L, Matzinger D, Merz M, Appel-Dingemans S, Osborne S, Luchinger S, Bertrix R, Maecke H, Beglinger C. Tegaserod, a S-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15:1745–51.
5. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:483–8.
6. De Maeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99–112.
7. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a S-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther. 2003;17:577–85.
8. Greenwood-Van Meerveld B, Venkova K, Hicks G, Dennis E, Crowell MD. Activation of peripheral 5-HT4 receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol Motil. 2006;18:76–86.
9. Grider JR, Fox-Orenstein AE, Jin JG. S-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology. 1998;115:370–80.
10. Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, Brooks EM, Zhao H, Swain GM, Moses PL, Galligan JJ, et al. Activation of colonic mucosal S-HT4 receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol Motil. 2006;18:76–86.
11. Ji SW, Park H, Chung JP, Lee SJ, Lee YH. Effects of tegaserod on ileal peristalsis of guinea pig in vitro. J Pharmacol Sci. 2004;94:142–52.
12. McGuire C, Boundouki G, Hockley JRF, Reed D, Cibert-Goton V, Peiris M, Kung V, Broad J, Azz Q, Chan C, et al. Ex vivo study of human visceral nociceptors. Gut. 2017;66:86–96.
13. Liu M, Ceddis MS, Wen Y, Setlik W, Gershon MD. Expression and function of S-HT4 receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2005;289:G148–63.
14. Grider JR. Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective S-HT4 agonist tegaserod. Am J Physiol. 2006;290:319–27.
15. Niedi T, White PJ, Coupar JM, Irving HR. Tissue dependent differences in G-protein coupled receptor kinases associated with S-HT4 receptor desensitization in the rat gastro-intestinal tract. Biochem Pharmacol. 2011;81:1223–33.
16. Ansaryesh H, Sebben M, Boekaert J, Dumuis A. Characterization of homologous S-hydroxytryptamine4 receptor desensitization in colliculi neurons. Mol Pharmacol. 1992;42:808–16.
17. Rondé P, Ansarysh H, Dumuis A, Miller R, Boekaert J. Homologous desensitization of S-hydroxytryptamine4 receptors in rat esophageal functional and second messenger studies. J Pharmacol Exp Ther. 1995;272:977–83.
18. Barhet G, Garrat G, Cressier E, Barker B, Gaven F, Pilloit M, Framery B, Pelissier JP, Augier J, Kang DS, et al. B-arrestin1 phosphorylation by GRK5 regulates G-protein-independent S-HT4 receptor signaling. EMBO J. 2009;28:270–8.
19. Barhet G, Gaven F, Framery B, Shinjo K, Nakamura T, Claesens S, Boekaert J, Dumuis A. Uncoupling and endocytosis of S-hydroxytryptamine 4 receptors: distinct molecular events with different GRK2 requirements. J Biol Chem. 2005;280:27924–34.
20. Mnie-Filali O, Amraei MG, BembaRek S, ArcherLahouc E, Peñas-Cazorla R, Vilão MT, Boye SM, Piheyro G. Serotonin 4 receptor (S-HT4R) internalization is isoform-specific: effects of S-HT and RS67333 on isoforms A and B. Cell Signal. 2010;22:501–9.
21. Ahmed MR, Gurevich V, Dalby KN, Benovic J, Gurevich EV. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther. 2008;325:276–83.
22. Fan X, Zhang J, Zhang X, Yue W, Ma L. Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain. Neuropharmacol. 2002;43:809–16.
23. Miraîles A, Asensio VI, García-Sevilla JA. Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein–coupled receptor kinases 2/3 in rat brain. Neurupharmacol. 2002;44:1249–57.
24. Diaz A, Paozo A, Florio J, Ayesta FI, Santana V, Hurle MA. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neurosci. 2002;112:345–53.
25. Hurle MA. Changes in the expression of G-protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001;77:486–92.
26. Gannetdinov RR, Premont RT, Bohn LM, LeKowitz RJ, Caron MG. Desensitization of G-protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107–44.
27. Armstrong SR, McCullough JL, Beattie DT. Measurement of S-HT4 receptor-mediated esophageal responses by digital sonomometry in the anesthetized rat. J Pharmacol Toxicol Meth. 2006;53:198–205.
28. Beattie DT, Armstrong SR, Shaw JP, Marquess D, Sandlund C, Smith JA, Taylor JA, Humphrey PP. The in vivo gastrointestinal activity of TD-5108, a selective S-HT(4) receptor agonist with high intrinsic activity. Naunyn-Schmiedeberg’s Arch Pharmacol. 2008;378:139–47.
29. McCullough JL, Armstrong SR, Hegde SS, Beattie DT. The S-HT2B antagonist and S-HT4 agonist activities of tegaserod in the anesthetized rat. Pharmacol Res. 2006;53:353–8.
30. Beattie DT, Smith JA, Marquess D, Vickers RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP. The S-HT4 receptor agonist, tegaserod, is a potent S-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004;143:549–60.
31. Baxter GS, Craig DA, Clarke DE. S-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn-Schmiedeberg’s Arch Pharmacol. 1991;343:439–46.
32. Poole DP, Xu B, Koh SL, Hunne B, Coupar IM, Irving HR, Shinjo K, Furness JB. Identification of neurons that express S-hydroxytryptamine-4 receptors in the intestine. Cell Tissue Res. 2006;325:413–22.
33. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol. 2007;69:511–34.
34. Bahouth SW, Nooh MM. Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks. Cell Signal. 2017;36:42–55.
35. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci. 1999;20:279–86.
36. Burgos-Ramos E, Puebla-Jimenez L, Antilla-Ferreiro E. Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience. 2008;154:1458–66.
37. Matuzany-Ruban A, Golan M, Miroshnik N, Schreiber G, Avissar S. Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants. Int J Neuropsychopharmacol. 2009;2009:1–9.

38. Wu H, Wei W, Song L, Zhang L, Chen Y, Hu X. Paeoniflorin induced immune tolerance of mesenteric lymph node lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. Int Immunopharmacol. 2007;7:662–73.

39. Dzimir N, Muiya P, Andres E, Al-Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol. 2004;489:162–77.

40. Grange-Midroit M, Garcia-Sevilla JA, Ferre-Alcon M, La Harpe R, Walzer C, Guimon J. G protein-coupled receptor kinases, beta-arrestin-2 and associated regulatory proteins in the human brain: postmortem changes, effect of age and subcellular distribution. Brain Res Mol Brain Res. 2002;101:39–51.